| |
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Today’s Big NewsJan 23, 2024 |
| By Max Bayer Johnson & Johnson CEO Joaquin Duato said he sees potential opportunities to bolster its neuroscience and immunology pipelines following the acquisition of Ambrx. The company recently paid $2 billion to acquire the ADC maker. |
|
|
|
By Nick Paul Taylor Sanofi has taken a surgical approach to its latest piece of M&A, agreeing to pay $1.7 billion to buy Inhibrx for below the market price but then spin out all but one of its candidates to create a new publicly traded biotech. |
By Nick Paul Taylor Novo Nordisk has piled yet another obesity program on its plate. Seeking to build on its early lead in the blockbuster market, the Danish drugmaker has agreed to pay EraCal Therapeutics up to 235 million euros ($255 million) to work on a novel mechanism of action for controlling appetite and body weight. |
Sponsored by Cardinal Health Cell and gene therapy patients often require support throughout their treatment journey. Learn key considerations for developing patient support programs. |
By James Waldron Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products. |
By Max Bayer Accent Therapeutics has tacked on two more Big Pharma backers, with J&J's venture arm and BMS joining the biotech's $75 million series C. The startup previously added AbbVie as an investor and is more than three years into a collaboration with AstraZeneca. |
By Gabrielle Masson Karuna Therapeutics was almost bought out by another large pharma that competed up until the last moment before Bristol Myers Squibb’s $14 billion proposal won out. |
By Max Bayer Roche is the latest large pharma to buy into GenEdit's nanoparticle delivery tech for gene editing therapies, paying $15 million upfront. The biotech previously added Eli Lilly as an investor and inked a partnership with Sarepta. |
By James Waldron Gene therapy developer Florida Biotechnologies is set to be acquired by fellow Floridians NAYA Biosciences for $20 million in shares as part of the portfolio-focused company’s search for disruptive clinical-stage therapies it can invest in. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Angus Liu As many have feared, the FDA's investigation into secondary T-cell malignancies following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. |
By Zoey Becker The new chief aims to strike M&A deals that will fill out Lundbeck's early pipeline as the company leans on growth drivers Rexulti and Vyepti. |
By Dave Muoio New letters and instructional materials out of HHS come amid reported contraception coverage barriers and escalating legal challenges over emergency abortion procedures. |
Fierce podcasts Don’t miss an episode |
| At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
